Substance Withdrawal Syndrome
Recent clinical, regulatory, research and industry developments relating to this disease.
Central amygdala astrocyte plasticity underlies GABAergic dysregulation in ethanol dependence.
Case analysis of long-term negative psychological responses to psychedelics.
Nucleus accumbens D1/D2 circuits control opioid withdrawal symptoms in mice.
Neurobiologic Advances from the Brain Disease Model of Addiction.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Substance Withdrawal Syndrome4
- Hallucinogens3
- Analgesics, Opioid2
- Acid Sensing Ion Channels1
- Alcoholism1
- Astrocytes1
- Central Amygdaloid Nucleus1
- Ethanol1
Leading journals6
- Clinical psychology & psychotherapy1
- International journal of molecular sciences1
- Journal of affective disorders1
- Scientific reports1
- The Journal of clinical investigation1
- The New England journal of medicine1
Leading researchers8
- Andrys NRR1
- Bremler R1
- Carhart-Harris RL1
- Chambers R1
- Chandler LJ1
- Dang W1
- Erritzoe D1
- Fan R1
Affiliations (unnormalised)6
- Center for Healthy Minds1
- Center for Psychiatry Research1
- Centre for Psychedelic Research1
- College of Forensic Science1
- Department of Psychiatry and Center for Brain Science1
- Department of Veterans Affairs Medical Center1
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Substance withdrawal syndrome is a set of physiological and psychological symptoms that occur after stopping a drug following prolonged use or habituation. It includes withdrawal associated with smoking, drinking, and withdrawal from administered drugs.
It is caused by withdrawal from a drug after prolonged administration or habituation. The grounding also includes withdrawal from smoking and drinking as part of the syndrome.
The syndrome involves physiological and psychological symptoms that emerge when a habituated substance is removed. The supplied grounding links it broadly to mental health, but does not provide a more specific biological mechanism.
Prolonged administration or habituation to a drug increases the likelihood of withdrawal symptoms when the substance is stopped. The grounding also indicates risk in the context of smoking and drinking withdrawal.
The literature grounding indicates drug therapy and therapy as treatment modalities. No specific drug classes or protocols are provided in the supplied material.
AI-generated summary grounded in MeSH. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.